Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) took place on 2–4 October 2026, in Washington DC. At this event, the world’s leading clinical researchers in MDS & MPNs shared their perspectives on how to place the evolving understanding of these hematological malignancies in a clinical context to optimize clinical care.
iwMDS 2026
The 4th International Workshop on MDS & MPNs
01–04 October 2026 | Washington DC, USA
The 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) took place on 2–4 October 2026, in Washington DC. At this event, the world’s leading clinical researchers in MDS & MPNs shared their perspectives on how to place the evolving understanding of these hematological malignancies in a clinical context to optimize clinical care.
Explore roundtable discussions and interviews
View all videos
Keynote talk
What is the current best practice in higher-risk MDS?
From CHIP to MDS
Diagnosis, classification and prognostication in MDS and MDS/MPN
What is the role of allo-SCT for the treatment of MDS?
Keynote talk
What are the right endpoints for future MDS clinical trials?
Quo vadis MDS? Where do we go from here? Short perspectives on future plans for clinical trials from around the world (Part 1)
Quo vadis MDS? Where do we go from here? Short perspectives on future plans for clinical trials from around the world (Part 2)
Novel targets in MDS
How should we think about MRD in MDS?
Keynote talk
icMDS: progress and future directions
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Coming soon
What is the current best practice in higher-risk MDS?
Venetoclax still has a role in higher-risk MDS: Yes
Yasmin Abaza Northwestern University, Chicago, IL, United States
Coming soon
Venetoclax still has a role in higher-risk MDS: No
Mikkael Sekeres Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon
How I will treat higher-risk MDS in 2027
Yazan Madanat UT Southwestern Medical Center, Dallas, TX, United States
Coming soon
Evolving antibodies in management of higher risk MDS
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Coming soon
Lessons learned from a decade of higher-risk MDS trials
Maximilian Stahl Yale Cancer Center, New Haven, CT, United States
Coming soon
Strategies for bridging HR-MDS patients to allogeneic transplantation
Klaus Metzeler University of Leipzig, Leipzig, Germany
Coming soon
From CHIP to MDS
Using the CHIVE registry to better understand risk of CH
Michael Savona Vanderbilt University, Nashville, TN, United States
Coming soon
How to design studies for CCUS and CHIP
Uma Borate Ohio State University, Columbus, OH, United States
Coming soon
Diagnosis, classification and prognostication in MDS and MDS/MPN
Incorporation of flow cytometry in diagnosis and classification of MDS
Arjan van de Loosdrecht Amsterdam UMC, Amsterdam, Netherlands
Coming soon
Prognostication in TP53-mutated MDS – is there any “good” subtype?
Tariq Kewan Yale School of Medicine, New Haven, CT, United States
Coming soon
How can AI help in MDS prognostication and management?
Matteo Della Porta Humanitas Research Hospital, Milan, Italy
Coming soon
Development of the icMDS-PRO score
Fabio Efficace Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, IL, Italy
Coming soon
What is the role of allo-SCT for the treatment of MDS?
Should we transplant TP53-mutated MDS patients?: No
Alain Mina National Cancer Institute, DC, WA, United States
Coming soon
Should we transplant TP53-mutated MDS patients?: Yes
Coming soon
Keynote talk
Clinical development of lenalidomide in LR-MDS a lesson in drug development
Alan List Precision BioSciences, Durham, NC, United States
Coming soon
What are the right endpoints for future MDS clinical trials?
What are the right endpoints for lower-risk and higher-risk MDS trials?
Rami Komrokji Moffitt Cancer Center, Tampa, FL, United States
Coming soon
Industry perspective on drug approval for MDS
Coming soon
FDA views on drug approval for MDS
Nina Kim U.S. Food & Drug Administration, Silver Spring, MD, United States
Coming soon
Statistical perspectives and trial designs for MDS
Coming soon
Clinical trial reporting in MDS
Andrew Brunner Massachusetts General Hospital, Boston, MA, United States
Coming soon
Quo vadis MDS? Where do we go from here? Short perspectives on future plans for clinical trials from around the world (Part 1)
CTEP views on use for novel agents in MDS
Steven Gore National Cancer Institute, Bethesda, MD, United States
Coming soon
Important US MDS trials
Olatoyosi Odenike Duchossois Center for Advanced Medicine, Chicago, IL, United States
Coming soon
The Canadian plan for MDS trials
Rena Buckstein Sunnybrook Health Sciences Centre
Coming soon
Quo vadis MDS? Where do we go from here? Short perspectives on future plans for clinical trials from around the world (Part 2)
The Chinese plan for MDS trials
Bing Li Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Coming soon
The Scandinavian plan for MDS trials
Coming soon
The Greek plan for MDS trials
Ioannis Kotsianidis Thrace University, School of Medicine, Alexandroupolis, Greece
Coming soon
The Australian plan for MDS trials
Lynette Chee The Royal Melbourne Hospital & Peter MacCallum Cancer Centre, Melbourne, Australia
Coming soon
Novel targets in MDS
What are the next promising targets for higher-risk MDS?
Hetty Carraway Cleveland Clinic, Cleveland, OH, United States
Coming soon
What are the next promising targets for lower-risk MDS?
Elizabeth Griffiths Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Coming soon
Targeting the TGF pathway and inflammation in MDS
Valeria Santini University of Florence, Florence, Italy
Coming soon
How should we think about MRD in MDS?
Flow cytometry for MRD in MDS
Arjan van de Loosdrecht Amsterdam UMC, Amsterdam, Netherlands
Coming soon
Clinical application and limitations of measurable residual disease in MDS
Andrew Brunner Massachusetts General Hospital, Boston, MA, United States
Coming soon
The iwMDS/MPN 2026 meeting was supported by:
